公开(公告)号：US09700524B2

公开(公告)日：2017-07-11

申请号：US15040002

申请日：2016-02-10

Applicant: NEONC Technologies, Inc.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC: A61K31/045 ,  C07C29/92 ,  C07C67/14 ,  C07C201/12 ,  C07C29/78 ,  C07C29/88 ,  C07C201/16 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10

CPC classification number: C07C29/92 ,  A61K31/045 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07B2200/07 ,  C07C29/78 ,  C07C29/86 ,  C07C29/88 ,  C07C67/14 ,  C07C201/12 ,  C07C201/16 ,  C07C2601/16 ,  C07C33/14 ,  C07C205/57 ,  C07C69/76 ,  C07C69/92

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US11479554B2

公开(公告)日：2022-10-25

申请号：US16876621

申请日：2020-05-18

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC: C07D487/04 ,  C07D231/12 ,  A61P35/00

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

公开(公告)号：US10457618B2

公开(公告)日：2019-10-29

申请号：US15220135

申请日：2016-07-26

Applicant: NEONC Technologies, Inc.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC: C07C29/92 ,  A61K31/045 ,  C07C67/14 ,  C07C201/12 ,  C07C29/78 ,  C07C29/88 ,  C07C201/16 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07C29/86

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US11559508B2

公开(公告)日：2023-01-24

申请号：US16606520

申请日：2018-04-18

Applicant: NEONC TECHNOLOGIES, INC.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC: A61K31/20 ,  A61K47/55 ,  A61K9/00 ,  A61K31/045 ,  A61K45/06

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US10696680B2

公开(公告)日：2020-06-30

申请号：US16126586

申请日：2018-09-10

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC: C07D487/04 ,  A61P35/00 ,  C07D231/12

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

公开(公告)号：US20190241568A1

公开(公告)日：2019-08-08

申请号：US16126586

申请日：2018-09-10

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish Puppali

IPC: C07D487/04 ,  A61P35/00 ,  C07D231/12

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

公开(公告)号：US20200277299A1

公开(公告)日：2020-09-03

申请号：US16876621

申请日：2020-05-18

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish Puppali

IPC: C07D487/04 ,  A61P35/00 ,  C07D231/12

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

公开(公告)号：US20170190710A1

公开(公告)日：2017-07-06

申请号：US15462553

申请日：2017-03-17

Applicant: NEONC TECHNOLOGIES INC.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC: C07D487/04 ,  C07D231/12

CPC classification number: C07D487/04 ,  C07D231/12

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

公开(公告)号：US09498448B2

公开(公告)日：2016-11-22

申请号：US14843097

申请日：2015-09-02

Applicant: NEONC Technologies, Inc.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC: C07C35/18 ,  A61K31/045 ,  C07C29/92 ,  C07C67/14 ,  C07C201/12 ,  C07C29/78 ,  C07C29/88 ,  C07C201/16 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10

CPC classification number: C07C29/92 ,  A61K31/045 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07B2200/07 ,  C07C29/78 ,  C07C29/86 ,  C07C29/88 ,  C07C67/14 ,  C07C201/12 ,  C07C201/16 ,  C07C2601/16 ,  C07C33/14 ,  C07C205/57 ,  C07C69/76 ,  C07C69/92

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US09480659B2

公开(公告)日：2016-11-01

申请号：US14817286

申请日：2015-08-04

Applicant: NEONC Technologies, Inc.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC: C07C35/18 ,  A61K31/045 ,  C07C29/92 ,  C07C67/14 ,  C07C201/12 ,  C07C29/78 ,  C07C29/88 ,  C07C201/16 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10

CPC classification number: C07C29/92 ,  A61K31/045 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07B2200/07 ,  C07C29/78 ,  C07C29/86 ,  C07C29/88 ,  C07C67/14 ,  C07C201/12 ,  C07C201/16 ,  C07C2601/16 ,  C07C33/14 ,  C07C205/57 ,  C07C69/76 ,  C07C69/92

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.